感覚受容体を除くGPCRをヒト 300種、マウス 250種、計550種取り揃え、共役するGαタンパク質のサブタイプに依らず単一フォーマットのアッセイで活性を評価します。 各受容体の詳細は表をクリックしてください。また、ラット、ウサギ、イヌ、カニクイザルなど他種のGPCRについてはお問い合わせください。
Filters Sort results
Reset Apply
Species | Receptor | Family | Assays | |
|---|---|---|---|---|
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Psychiatry ⋅ Gastrointestinal ⋅ à la carte |  Reference agonist: histamine EC50: 240 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Psychiatry ⋅ Neurology ⋅ Cardiology ⋅ à la carte |  Reference agonist: histamine EC50: 190 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Oncology ⋅ Gastrointestinal ⋅ Dermatology ⋅ à la carte |  Reference agonist: histamine EC50: 51 nM | ||
Human | Assay modes: - Panels: - | Reference agonist: EC50: | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Ophthalmology ⋅ Dermatology ⋅ à la carte |  Reference agonist: nicotinic acid EC50: 5.8 µM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Dermatology ⋅ à la carte |  Reference agonist: 3‐OH‐octanoic acid EC50: 130 µM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Oncology ⋅ Endocrinology/Metabolism ⋅ Neurology ⋅ Ophthalmology ⋅ Gastrointestinal ⋅ Dermatology ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: kisspeptin‐10 EC50: 1.3 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Gastrointestinal ⋅ à la carte |  Reference agonist: LTB4 EC50: 84 pM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: LTB4 EC50: 36 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Hematology ⋅ Respiratory ⋅ à la carte |  Reference agonist: LTD4 EC50: 7.9 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Oncology ⋅ Ophthalmology ⋅ Respiratory ⋅ à la carte |  Reference agonist: LTD4 EC50: 400 pM | ||
Human | Assay modes: - Panels: - | Reference agonist: EC50: | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Hematology ⋅ Ophthalmology ⋅ Cardiology ⋅ Respiratory ⋅ Gastrointestinal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: CH3‐carbamyl PAF C‐16 EC50: 840 pM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Oncology ⋅ Gastrointestinal ⋅ Dermatology ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: LPA EC50: 400 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: - |  Reference agonist: LPA EC50: 1.7 µM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Oncology ⋅ Ophthalmology ⋅ à la carte |  Reference agonist: LPA EC50: 1.3 µM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: LPA EC50: 2.1 µM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: LPA EC50: 3.0 µM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Ophthalmology ⋅ Dermatology ⋅ à la carte |  Reference agonist: LPA EC50: 750 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Oncology ⋅ Hematology ⋅ à la carte |  Reference agonist: S1P EC50: 120 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Hematology ⋅ Endocrinology/Metabolism ⋅ à la carte |  Reference agonist: S1P EC50: 96 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: S1P EC50: 48 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: S1P EC50: 210 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: MCH EC50: 37 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: MCH EC50: 2.1 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Oncology ⋅ Endocrinology/Metabolism ⋅ Neurology ⋅ Ophthalmology ⋅ Dermatology ⋅ Musculoskeletal ⋅ à la carte |  Reference agonist: α‐MSH EC50: 850 pM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Endocrinology/Metabolism ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: ACTH EC50: 4.1 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: α‐MSH EC50: 180 pM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Endocrinology/Metabolism ⋅ à la carte |  Reference agonist: α‐MSH EC50: 600 pM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: α‐MSH EC50: 8.5 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Ophthalmology ⋅ à la carte |  Reference agonist: melatonin EC50: 100 pM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Endocrinology/Metabolism ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: melatonin EC50: 95 pM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Oncology ⋅ Neurology ⋅ Ophthalmology ⋅ Dermatology ⋅ Musculoskeletal ⋅ à la carte |  Reference agonist: L‐glutamic acid EC50: 6.4 µM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Psychiatry ⋅ à la carte |  Reference agonist: L‐glutamic acid EC50: 6.4 µM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: L‐glutamic acid EC50: 34 µM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: - |  Reference agonist: L‐glutamic acid EC50: 5.9 µM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Ophthalmology ⋅ à la carte |  Reference agonist: L‐glutamic acid EC50: 190 µM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Psychiatry ⋅ à la carte |  Reference agonist: L‐glutamic acid EC50: 26 µM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: motilin EC50: 590 pM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: NMU‐23 EC50: 1.3 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: NMU‐23 EC50: 390 pM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: NPFF EC50: 22 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: NPFF EC50: 280 pM | ||
Human | Assay modes: - Panels: - | Reference agonist: EC50: | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: NPW‐30 EC50: 20 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: NPW‐30 EC50: 14 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Endocrinology/Metabolism ⋅ Psychiatry ⋅ Neurology ⋅ à la carte |  Reference agonist: NPY EC50: 840 pM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Endocrinology/Metabolism ⋅ Psychiatry ⋅ Neurology ⋅ à la carte |  Reference agonist: NPY EC50: 4.6 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: NPY EC50: 29 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Hematology ⋅ Endocrinology/Metabolism ⋅ à la carte |  Reference agonist: NPY EC50: 7.6 nM |
